SRPT vs. IONS, JAZZ, MRTX, RARE, TAK, ALNY, TEVA, GMAB, RPRX, and BMRN
Should you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Takeda Pharmaceutical (TAK), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "pharmaceutical preparations" industry.
Ionis Pharmaceuticals (NASDAQ:IONS) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings.
93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 2.7% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 7.7% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Ionis Pharmaceuticals has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.
Sarepta Therapeutics has a net margin of 1.20% compared to Sarepta Therapeutics' net margin of -49.49%. Ionis Pharmaceuticals' return on equity of 2.20% beat Sarepta Therapeutics' return on equity.
Sarepta Therapeutics received 753 more outperform votes than Ionis Pharmaceuticals when rated by MarketBeat users. Likewise, 75.34% of users gave Sarepta Therapeutics an outperform vote while only 60.33% of users gave Ionis Pharmaceuticals an outperform vote.
Ionis Pharmaceuticals has higher earnings, but lower revenue than Sarepta Therapeutics. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Ionis Pharmaceuticals currently has a consensus price target of $60.18, suggesting a potential upside of 16.96%. Sarepta Therapeutics has a consensus price target of $187.72, suggesting a potential upside of 30.15%. Given Ionis Pharmaceuticals' higher possible upside, analysts clearly believe Sarepta Therapeutics is more favorable than Ionis Pharmaceuticals.
In the previous week, Ionis Pharmaceuticals had 21 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 32 mentions for Ionis Pharmaceuticals and 11 mentions for Sarepta Therapeutics. Ionis Pharmaceuticals' average media sentiment score of 0.82 beat Sarepta Therapeutics' score of 0.69 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.
Summary
Sarepta Therapeutics beats Ionis Pharmaceuticals on 14 of the 19 factors compared between the two stocks.
Get Sarepta Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sarepta Therapeutics Competitors List
Related Companies and Tools
